Clinical data from 40 patients with unresectable or recurrent CCA who received gemcitabine (1000 mg/m2) plus cisplatin (25 mg/m2) demonstrated that hENT1 expression was associated with treatment outcomes. This evidence concerns the gene SLC29A1 and cholangiocarcinoma.